Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 4,500 Shares

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur purchased 4,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 24th. The stock was bought at an average cost of $4.65 per share, with a total value of $20,925.00. Following the purchase, the chief executive officer now owns 3,270,924 shares of the company’s stock, valued at $15,209,796.60. This represents a 0.14 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ron Bentsur also recently made the following trade(s):

• On Friday, November 15th, Ron Bentsur bought 20,000 shares of Nuvectis Pharma stock. The stock was purchased at an average cost of $4.92 per share, for a total transaction of $98,400.00.

Nuvectis Pharma Trading Up 4.0 %

Shares of Nuvectis Pharma stock opened at $5.22 on Friday. The company has a 50 day moving average of $6.26 and a 200-day moving average of $6.46. The company has a market cap of $100.86 million, a PE ratio of -4.50 and a beta of 0.20. Nuvectis Pharma, Inc. has a 1-year low of $4.44 and a 1-year high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. During the same period last year, the firm posted ($0.37) EPS. Research analysts forecast that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current year.

Institutional Investors Weigh In On Nuvectis Pharma

A number of hedge funds have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in Nuvectis Pharma during the 2nd quarter worth approximately $58,000. Nations Financial Group Inc. IA ADV bought a new stake in shares of Nuvectis Pharma during the third quarter worth $63,000. GSA Capital Partners LLP increased its holdings in shares of Nuvectis Pharma by 3.7% during the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after buying an additional 1,790 shares in the last quarter. Iridian Asset Management LLC CT bought a new position in shares of Nuvectis Pharma in the 3rd quarter valued at $348,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Nuvectis Pharma by 20.7% during the 2nd quarter. Renaissance Technologies LLC now owns 74,500 shares of the company’s stock valued at $472,000 after acquiring an additional 12,800 shares in the last quarter. 96.77% of the stock is currently owned by institutional investors and hedge funds.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.